NCT00761670View on ClinicalTrials.gov

Efficacy Study on Cognitive Functions in Schizophrenic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Schizophrenia
Interventions
DRUG

amisulpride and risperidone

amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Budapest

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY